Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02424786
Other study ID # 15-068
Secondary ID
Status Completed
Phase N/A
First received March 31, 2015
Last updated September 19, 2017
Start date May 2015
Est. completion date September 2017

Study information

Verified date September 2017
Source University Hospital, Akershus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to investigate adherence and polypharmacy in elderly patients with chronic kidney disease (CKD) and End Stage Renal Disease (ESRD). The investigators look into possible factors or predictors that may affect adherence and reduce polypharmacy. Factors could be: quality of life, anxiety and depression, beliefs about medicine and cognitive impairment.

The investigators are planning an intervention with the screening tool Screening Tool of Older Person's potentially inappropriate Prescription/Screening tool to Alert to Right Treatment (STOPP/START ) criteria to evaluate medication lists of the participating patients.


Description:

The investigators intend to include all patients > 65 years old, in dialysis treatment (hemodialysis and peritoneal dialysis), as well as patients with CKD stage 5.

The recruitment will be done as follows:

The patients will be screened according to inclusion criteria. Afterwards each patient will be invited to a first meeting that explains the aim of the study, giving the opportunity for discussion and consideration, and presenting the consent information. After giving the consent the patient will be invited to a second meeting with blood tests, data registration, medication registration, undergoing MMS and handing over the questionnaires forms.

Randomization:

After the initial assessment and compliance with the eligibility criteria, participants will be randomized into an intervention group (medication list will be evaluated by STOPP/START criteria) and a control group (medication list will not be evaluated by STOPP/START criteria). Randomization numbers will be generated by a random number generator. A series of numbered, sealed, opaque envelopes will be used to ensure confidentiality. Each envelope will contain a card with information about the group allocation. The group allocation is concealed from the researcher and patients at baseline registration.

Each patients will get questionnaires for: Quality of life using Kidney Disease Quality of Life - Short form 36 (KDQOL-Short form 36 ) and EuroQoL-3D (EQ-3D), beliefs about medicine, Hospital Anxiety and Depression Scale (HADS), Morisky medication adherence scale and visual adherence scale (VAS), sleeping related questionnaires (Epworth, Berlin, Pittsburgh). A Mini Mental Status (MMS) test will be done regarding cognitive function.

Each patients will get the opportunity to have a polysomnograph for one night.

With STOPP/START criteria the medication list will be evaluated for the patients who are randomized in the intervention group.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date September 2017
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- All patients > 65 years with CKD, stage 5 (eGFR = 12 ml/min), or undergoing treatment with hemodialysis and peritoneal dialysis

Exclusion Criteria:

- Patients not willing to participate

- Patients diagnosed with dementia or severe cognitive disorder (MMS < 25),

- Patients with hearing impairment

- Patients with language difficulties

Study Design


Related Conditions & MeSH terms


Intervention

Other:
STOPP/START criteria
Evaluation of medication lists

Locations

Country Name City State
Norway Vestre Viken Sykehus Drammen
Norway University Hospital, Akershus Oslo
Norway University Hospital, Ullevål Oslo

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Akershus

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline regarding prescription of inappropriate medications in the intervention group Improvement of polypharmacy baseline and 6 months
Other Change from baseline in Morisky medication adherence scale and visual adherence scale Difference between Morisky medication scale score and score from the Visual adherence score baseline
Primary Prevalence for medication non-adherence Adherence measured by Morisky medication adherence scale and visual adherence scale 6 months - 1 year
Secondary Improvement of polypharmacy Randomization of all patients into intervention group and control group. Comparing both groups by using STOPP/START criteria with the aim to assess numbers of patients with inappropriate medications 1-2 year
Secondary Improvement of adherence Randomization of all patients into intervention group and control group with the aim to improve adherence by using Morisky medication adherence scale and visual adherence scale 1-2 year
Secondary Association between beliefs about medication and anxiety and depression with medication non-adherence and quality of life Questionnaires about: Beliefs about medicine, depression and anxiety (measured by HADS), quality of life (measured by KDQOL-Short form 36, EQ-5D), and adherence (measured by Morisky medication adherence scale and visual adherence scale) 1-2 years
Secondary Predictors for medication non-adherence Questionnaires about depression and anxiety (HADS) 6 months - 1 year
Secondary Risk factors for medication non-adherence Questionnaires about beliefs about medicine 6 months - 1 year
Secondary Medication non-adherence risk factors Questionnaires about sleep quality (Epworth, Berlin, Pittsburgh questionnaires) 6 months - 1 year
Secondary Non-adherence and medication - predictors Questionnaires about quality of life measured by KDQOL-Short form 36 and EQ-5D 6 months - 1 year
See also
  Status Clinical Trial Phase
Completed NCT02858050 - Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications
Completed NCT01957865 - Real-Time Antiretroviral Therapy Adherence Intervention in Uganda N/A
Completed NCT01696331 - Text Messaging for Adherence in Adolescent Liver Transplant Recipients N/A
Completed NCT02041390 - Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases N/A
Completed NCT00218452 - Smoking Cessation for Young Adults Who Binge Drink - 1 Phase 0
Recruiting NCT06351007 - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) N/A
Completed NCT02336334 - Evaluation of Posturing-Adherence in Patients After Intraocular Surgery N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02135003 - Non-enrolment and Non-adherence to HIV Care in a Community-based Program, Rakai, Uganda N/A
Recruiting NCT02621008 - Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss N/A
Completed NCT01247181 - Cameroon Mobile Phone SMS Trial N/A
Recruiting NCT05369845 - Observance of Continuous Positive Pressure for the Treatment of Obstructive Sleep Apnea Syndrome N/A
Completed NCT01118767 - Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru N/A
Active, not recruiting NCT03142256 - 3Ps for Prevention Study (Perception, Partners, Pills) Phase 4
Withdrawn NCT02468544 - Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention N/A
Active, not recruiting NCT01509014 - Community Pharmacy Assisting in Total Cardiovascular Health N/A
Recruiting NCT04557293 - Effort-based Decision-making and CPAPadherence N/A
Terminated NCT02822755 - Home Exercise Adherence in Physical Therapy N/A
Completed NCT01120704 - Evaluation of Treatments to Improve Smoking Cessation Medication Adherence Phase 4
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A